Ignite Creation Date:
2024-05-05 @ 5:09 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00392171
Status:
COMPLETED
Last Update Posted:
2017-06-07
First Post:
2006-10-24
Brief Title:
The Effects of Continuous 28-day 2828 Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day 528 Treatment P04601
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Organization Data
Organization:
Merck Sharp Dohme LLC
Class:
INDUSTRY
Study ID:
P04601
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Merck Sharp Dohme LLC
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None